Recent studies have shown that SPEN is mutated in 5% of splenic marginal zone lymphoma cases [48], and SPEN functions as a tumor repressor and candidate biomarker of tamoxifen responsiveness in ERα-positive breast cancers [49]. This evidence concerns the gene SPEN and splenic marginal zone lymphoma.